Invivyd与美国FDA就Liberty三期试验达成一致,将评估VYD2311抗体对比mRNA新冠疫苗安全性并探索抗体与疫苗联合使用的安全性与免疫学特征

美股速递
Feb 03

Invivyd公司已与美国食品药品监督管理局就Liberty三期临床试验方案达成共识。该试验旨在评估其研发的VYD2311抗体药物与mRNA新冠疫苗在安全性方面的对比数据,同时系统研究抗体与疫苗联合给药时的安全性和免疫学反应特征。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10